Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss supportive care considerations for patients receiving T-cell redirecting therapies, with a focus on infection prevention and mitigation of cytokine release syndrome (CRS) during bispecific antibody step-up dosing.
Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss evolving treatment strategies for early relapse and relapsed/refractory multiple myeloma, focusing on recent evidence for T-cell redirecting therapies.
Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor discuss individualized treatment selection and sequencing in multiple myeloma as increasingly effective therapies expand available options.
Dr. Hans Lee and Dr. Prashant Kapoor discuss the evolving role of treatment duration and de-escalation in multiple myeloma, particularly for patients who achieve deep and sustained responses.
In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life.
In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease.
Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.
